Ubiquinone

Introduction Overview

Generic Name

Ubiquinone

Brand Name

Adelir, Coenzyme Q10, Heartcin, Inokiton, Neuquinone, Taidecanone, Udekinon

Dosage Form

Compressed tablets, chewable tablets, powder-filled capsules, gel-filled capsules, liquid syrups, wafers, solubilized formulations

Drug Class

Nutraceutical, Coenzyme Q10 (oxidized form)

Pharmacokinetics

Absorption: Ubiquinone is a lipid-soluble benzoquinone absorbed through the intestinal tract. Due to its lipophilic nature, its bioavailability is variable and influenced by formulation type and dietary fat intake. Pharmacokinetic studies indicate that split dosing (dividing total daily dose into multiple administrations) leads to superior plasma levels and tissue uptake compared to single daily dosing, especially important for crossing the blood-brain barrier and achieving therapeutic levels in target tissues. Distribution: After absorption, ubiquinone is incorporated into lipoproteins and distributed via the bloodstream to various organs, particularly the heart, liver, kidneys, and skeletal muscle, reflecting high mitochondrial content. Being highly lipophilic, ubiquinone accumulates within mitochondrial membranes. Plasma protein binding is high due to its hydrophobicity. Ubiquinol, the reduced form, is present ubiquitously in cellular membranes and acts as an antioxidant. Metabolism: Ubiquinone undergoes reduction to ubiquinol within cells, which participates actively in the mitochondrial electron transport chain and serves antioxidant functions. It undergoes redox cycling between its oxidized and reduced forms within mitochondrial membranes. Metabolic biotransformation appears primarily mitochondrial, with limited involvement of hepatic cytochrome P450 enzymes. The compound’s redox status modulates various membrane functions, including sodium/hydrogen ion antiporter activity and apoptosis regulation. Elimination: Excretion is primarily biliary into feces, with minimal renal elimination. Clinical studies indicate no significant accumulation in plasma or tissues after cessation of supplementation, suggesting efficient clearance and homeostatic regulation. Endogenous biosynthesis of coenzyme Q10 is not suppressed by exogenous intake. The elimination half-life is influenced by tissue uptake and individual metabolic status. Overall, pharmacokinetic parameters emphasize the need for dosage form optimization and dosing regimen consideration for clinical efficacy.

Dosage Forms

Available Dosage Forms: Ubiquinone is commercially available in several dosage forms to accommodate patient preferences and therapeutic indications. These include compressed tablets, chewable tablets, powder-filled capsules, gel-filled capsules, liquid syrups, wafers, and newer solubilized formulations. Additionally, the reduced form, ubiquinol, is available as a dietary supplement. Dosages for Adults and Adolescents: Clinical trials and therapeutic use primarily employ dosages ranging from 100 mg to 300 mg per day for general cardiovascular or neurologic indications. Higher doses up to 1,200 mg/day have been used safely in specific populations such as patients with end-stage renal disease or early Parkinson disease, and doses as high as 2,700 to 3,000 mg/day have been employed in amyotrophic lateral sclerosis studies. Split dosing divided into two or three administrations per day is recommended for improved absorption and tissue uptake. A daily dose of 400 mg was used effectively in studies on diabetic neuropathy. In Friedreich’s ataxia, idebenone (an analog) is used at about 5 mg/kg/day, up to 300 mg/day. Specific Patient Populations: In patients with congestive heart failure, a maintenance dose of 300 mg daily is often investigated. End-stage renal disease patients at high cardiac risk have demonstrated benefits at 1,200 mg/day in clinical trials. Pediatric dosing data is limited; however, high-dose idebenone (60 mg/kg/day divided into three doses) was studied in children with Friedreich’s ataxia. Pharmacokinetic data support split dosing in all populations for optimal therapeutic effect. Clinical guidelines caution about the lack of established safety data in pregnancy and lactation; therefore, use is not recommended in these populations.

Mechanism Of Action

Ubiquinone serves as a critical component of the mitochondrial electron transport chain, acting as a mobile electron carrier between complexes I and II to complex III. It facilitates the transfer of electrons via a redox process, cycling between its oxidized (ubiquinone) and reduced (ubiquinol) states, thereby enabling efficient ATP production through oxidative phosphorylation. This central bioenergetic role ensures cellular energy homeostasis, especially in tissues with high metabolic demand such as cardiac and skeletal muscle.

Beyond its role in electron transport, ubiquinol acts as a potent antioxidant localized within mitochondrial and cellular membranes. It protects lipids and proteins from oxidative damage by reducing reactive oxygen species and regenerating other antioxidants such as vitamin E and vitamin C. This reduction of oxidative stress may contribute to improved mitochondrial function and cellular resilience in pathologic states characterized by mitochondrial dysfunction.

Additional biochemical activities include the modulation of membrane fluidity and activation of membrane ion transporters, such as the sodium/hydrogen antiporter, which influence intracellular pH regulation and apoptotic pathways. Ubiquinone also impacts the redox state of nicotinamide adenine dinucleotide (NAD+/NADH), modulating key metabolic and signaling pathways involved in cell survival and aging.

Clinical studies investigating ubiquinone illustrate its ability to improve myocardial contractility and functional capacity, particularly in heart failure patients, likely via enhanced mitochondrial bioenergetics and reduced oxidative injury. Comparative studies with idebenone, a synthetic analog with more hydrophilic properties, reveal differences in pharmacokinetics and possibly tissue penetration, though both share similar mechanisms underpinning mitochondrial support and antioxidant effects. Research continues to elucidate the extent to which these molecular actions translate into clinical efficacy across various disease states.

Pharmacological Actions

Acts as an electron carrier in mitochondrial respiratory chain facilitating ATP synthesis.
Functions as an antioxidant protecting cellular membranes from oxidative damage.
Regenerates other antioxidants, including Vitamin E and Vitamin C, enhancing overall antioxidant defense.
Modulates membrane-associated ion transporters, including sodium/hydrogen antiporter, influencing cellular pH and apoptosis.
Regulates intracellular redox balance via NAD+/NADH modulation.
Enhances myocardial contractility by improving mitochondrial bioenergetics.
Improves endothelial function and arterial stiffness through lipid profile modulation and oxidative stress reduction.
Potentially reduces oxidative stress biomarkers in patients with end-stage renal disease.
Counteracts statin-induced depletion of endogenous coenzyme Q10, possibly ameliorating associated myopathy symptoms.
Exerts protective mitochondrial effects in neurodegenerative conditions, though clinical benefit remains inconclusive.
Supports improvement of exercise tolerance and immune system stimulation in experimental models.
Influences apoptosis control and mitochondrial function in various cell types.
Demonstrates antiangiogenic effects in combination with certain chemotherapeutics.
Participates in chemiosmotic coupling of proton translocation to respiration.

Therapeutic Or Clinical Uses

Adjunctive therapy in congestive heart failure to improve cardiac function and reduce mortality risk.
Supportive treatment in neurodegenerative diseases including Parkinson’s disease, although efficacy is not consistently demonstrated.
Management of mitochondrial disorders and coenzyme Q10 deficiency syndromes.
Potential use to improve endothelial function and reduce arterial stiffness in hypercholesterolemia.
Reversal support for statin-associated myopathy by supplementing coenzyme Q10 levels.
Migraine prophylaxis to reduce attack frequency and severity, based on certain clinical guidelines.
Adjunct in diabetic neuropathy to improve neuropathic symptoms and nerve conduction.
Investigational use in Friedreich’s ataxia to reduce ventricular hypertrophy and improve muscular bioenergetics.
Proposed benefit in cardiac surgery to improve mitochondrial function and myocardial contractility.
Supplementation to counteract oxidative stress in patients with end-stage renal disease.
Investigational use for amelioration of oxidative damage in cancer patients under specific chemotherapeutic regimens.
Supporting male fertility by improving sperm motility and concentration in subfertility cases.
Potential antioxidative protection in aging and immune system stimulation.
Use as a dietary supplement to enhance general cellular energy metabolism.

Side Or Adverse Effects

Gastrointestinal discomfort including diarrhea, nausea, vomiting, and dyspepsia.
Headache and fatigue reported in clinical trials with high-dose ubiquinone or idebenone.
Loss of appetite in some patients.
Allergic reactions including tongue swelling.
Rare instances of severe gastrointestinal bleeding associated with angiodysplasia.
Urine discoloration without accompanying laboratory abnormalities.
Mild abdominal discomfort reported, recommending caution in patients with hepatic dysfunction.
Potential for fibrotic changes in myocardium noted in isolated case studies, though causality not established.
Occasional difficulty chewing wafers in clinical trial settings.
No significant renal toxicity or accumulation observed.
No notable suppression of endogenous biosynthesis upon supplementation.
Generally well tolerated at doses up to 1,200 mg/day and higher in clinical studies.
Mild muscle-related symptoms reported but not definitively linked to ubiquinone use.
Potential for rare hypersensitivity reactions.
Mild headache reported in some clinical investigations.

Precautions

Use with caution in patients with hepatic dysfunction due to potential for abdominal discomfort.
Monitor concomitant use with vitamin K antagonists as ubiquinone may alter anticoagulant effects.
Avoid discontinuation without medical advice in patients on chronic therapy to prevent loss of potential benefits.
Caution advised due to limited safety data in pregnancy and lactation; not recommended during these periods.
Consider potential drug interactions when administered with anticoagulants or drugs affecting mitochondrial function.
Patients with known allergies to ubiquinone or excipients should avoid use.
Monitor for signs of gastrointestinal intolerance in sensitive individuals.
Careful assessment advised in patients undergoing cardiac surgery or with complex cardiac conditions.
Use caution in pediatric populations due to limited data; high-dose idebenone studies suggest tolerability.
Patients with mitochondrial disorders should have therapy guided by specialist consultation.
Consider dosage splitting to improve tolerance and pharmacokinetics.
Evaluate creatine kinase levels in patients using statins concurrently to monitor muscle effects.
Patients with bleeding disorders should be monitored closely given potential interaction effects.
Use with caution in elderly patients due to altered pharmacokinetics and increased sensitivity.
Patient education on possible mild side effects and importance of adherence to dosing schedules is recommended.

Warnings

Lack of consensus on efficacy for many indications; use supported primarily as adjunctive or supplemental therapy.
No absolute contraindications identified but careful monitoring in vulnerable populations is advised.
Potential to diminish or enhance effects of vitamin K antagonists necessitates close INR monitoring.
Safety and effectiveness in pregnant and lactating women are undetermined; use only if clearly needed.
High doses (greater than 1,200 mg/day) used in trials without severe adverse events but require clinical supervision.
Not FDA-approved for treatment of any condition; available as dietary supplement which has not undergone rigorous efficacy trials.
Patients should inform healthcare providers of use before surgical procedures due to possible interactions.
Rare serious adverse events reported, including severe GI bleeding, require prompt evaluation if symptoms develop.
Long-term safety data beyond several years not established.
Conflicting interaction profiles with other complementary and alternative medicine agents necessitate vigilance.
Supplement use should not replace standard therapies, especially in chronic diseases like heart failure or neurological disorders.
May produce mild GI side effects causing non-adherence if not managed properly.
Observed improvements in mitochondrial function have not been uniformly correlated with clinical outcomes.
Immunomodulatory claims not sufficiently proven; not recommended for immune disorders without further evidence.
Patients with mitochondrial encephalomyopathies should be managed under specialist guidance due to complexity of condition.

Contraindication

No absolute contraindications have been identified to date.
Known hypersensitivity to ubiquinone or any formulation component.
Use caution in patients with bleeding disorders pending careful monitoring due to interaction potential with anticoagulants.
Cautious use or avoidance recommended in pregnancy and lactation due to insufficient safety data.
Not recommended for children under 2 years of age due to lack of evidence.
Avoid substitution for prescribed therapies in chronic or life-threatening conditions.
Avoid uncontrolled concurrent use with multiple antioxidant supplements without medical supervision.
Contraindicated in patients with known allergy or previous adverse reaction to coenzyme Q10 supplements.
Avoid in patients with severe liver impairment without specialist consultation.
Not indicated as monotherapy for mitochondrial diseases or cardiovascular conditions.
Patients with active gastrointestinal bleeding should avoid until stabilized.
Avoid use in patients undergoing elective surgery unless advised by healthcare provider.
Not to be used as a cancer treatment due to absence of supportive evidence.
Contraindicated for use in Parkinson disease as a proven disease-modifying agent due to lack of efficacy.

Drug Interactions

May diminish the anticoagulant effect of vitamin K antagonists such as warfarin, necessitating close INR monitoring.
May also enhance anticoagulant effects in some cases; interaction profile is variable and requires individualized assessment.
Potential interaction with statins by mitigating statin-induced coenzyme Q10 depletion and associated myopathy.
Concurrent use with other antioxidants may affect redox balance, altering efficacy or side effect profiles.
Limited and conflicting data regarding interactions with other cardiovascular drugs; careful monitoring recommended.
Potential effects on drugs influencing mitochondrial function, such as certain chemotherapeutics, require close observation.
No significant pharmacokinetic interactions reported with commonly used diabetic medications.
May interfere with coagulation parameters when combined with antiplatelet agents; clinical significance undetermined.
Coadministration with ezetimibe does not protect against coenzyme Q10 depletion induced by statins.
Interactions with herbal supplements such as garlic or red yeast rice are plausible but not clearly established.
No evidence of significant interaction with non-steroidal anti-inflammatory drugs (NSAIDs).
Possible alteration of cytochrome P450 enzyme activity is minimal due to ubiquinone’s primary mitochondrial metabolism.
Monitoring advised when combined with hypoglycemic agents to detect potential additive effects on blood pressure or lipids.
Potential interference with clinical assay measurements of oxidative stress biomarkers.
Patients should disclose all supplements to healthcare providers to evaluate for possible interactions.

Preparations Of The Drug

Compressed tablets of various strengths, commonly 100 mg and 300 mg.
Chewable tablets designed for easier administration and improved compliance.
Powder-filled capsules providing controlled release and improved bioavailability.
Gel-filled capsules facilitating enhanced solubility of the lipophilic compound.
Liquid syrup formulations intended for pediatric or those with swallowing difficulties.
Wafer formulations enabling rapid dissolution and alternative administration route.
Solubilized coenzyme Q10 preparations designed to enhance absorption kinetics.
Reduced form ubiquinol supplements marketed for improved bioavailability.
Combination formulations with red yeast rice or other nutraceuticals targeting lipid and vascular health.
High-dose idebenone capsules used in specific investigational applications such as Friedreich’s ataxia.
Over-the-counter supplement products available in capsules, tablets, and liquid forms without prescription.
Standardized extracts with specific coenzyme Q10 content verified by HPLC or electrochemical detection methods.
Packaged in various dosages for titration and clinical trial use.
Formulations intended for oral administration only, with no parenteral preparations approved.
Dietary supplements available globally with varying regulatory status based on country.